Severe difficulties with eating in ME/CFS

That sounds a bit like Hirschsprung's disease with ganglionic agenesis (rather than diarrhoea in the Shy-Drager picture). Clearly this is a complicated field. I think the simple point is that people with ME/CFS don't really have generalised dysautonomia - of whatever sort.
I think lots of us have symptoms like this that aren’t pots. And meet most of these in the general bug then things like the pupils or the sweating might be a different pattern etc

But I’m guessing there is something technical I’m missing that makes it not dysautonomia?
 
I have not heard of any link betwen Sjogren's and dysautonomia but 'Sjogren's' is treated by some as one of those categories that can spread out in to almost anything. I think it becomes largely meaningless at that point.
That's what I see in a popular textbook of rheumatology FIRESTEIN & KELLEY’S TEXTBOOK OF RHEUMATOLOGY,
TWELFTH EDITION, Chapter 74 "Sjogren's syndrome" by E. WILLIAM ST. CLAIR AND DAVID L. LEVERENZ, page 1287:


Peripheral nervous system involvement is among the most
common of the extraglandular features of primary Sjögren’s
syndrome. In a cross-sectional study, peripheral neuropathy was
diagnosed in 17 (27%) of 62 patients with the primary type on
the basis of a conventional neurologic examination.126 However,
only 34 (55%) of the patients with primary Sjogren’s syndrome
in this group had abnormal nerve conduction velocity studies,
including 19 (31%) with a motor neuropathy, 8 (13%) with a
sensory neuropathy, and 7 (11%) with a sensorimotor neuropathy.
In this study, two patients with normal nerve conduction
velocity studies were diagnosed with a small-fiber neuropathy,
which is characterized by the loss of nerve fibers less than 7
micrometers, and thus cannot be assessed by conventional nerve
conduction studies.127 Small-fiber neuropathies are increasingly
recognized in a large proportion of patients with primary
Sjögren’s syndrome, although the true prevalence is unknown.
Typically, small-fiber neuropathies present with painful neuropathic
symptoms and may be associated with autonomic dysfunction,
such as vasomotor symptoms, hyperhidrosis, and
orthostasis.
127


Another example is cross-sectional study of a UK cohort of 317 patients with PSS (https://doi.org/10.1136/annrheumdis-2011-201009)

Methods​

Multicentre, prospective, cross-sectional study of a UK cohort of 317 patients with clinically well-characterised PSS. Symptoms of autonomic dysfunction were assessed using a validated instrument, the Composite Autonomic Symptom Scale (COMPASS). The data were compared with an age- and sex-matched cohort of 317 community controls. The relationships between symptoms of dysautonomia and various clinical features of PSS were analysed using regression analysis.

Results​

COMPASS scores were significantly higher in patients with PSS than in age- and sex-matched community controls (median (IQR) 35.5 (20.9–46.0) vs 14.8 (4.4–30.2), p<0.0001). Nearly 55% of patients (vs 20% of community controls, p<0.0001) had a COMPASS score >32.5, a cut-off value indicative of autonomic dysfunction. Furthermore, the COMPASS total score correlated independently with EULAR Sjögren's Syndrome Patient Reported Index (a composite measure of the overall burden of symptoms experienced by patients with PSS) (β=0.38, p<0.001) and disease activity measured using the EULAR Sjögren's Syndrome Disease Activity Index (β=0.13, p<0.009).




I haven't dug into the question, but I have heard from patients and Sjögren's advocates that autonomic dysfunction is disabling and often dismissed by physicians and ignored in clinical trials.

In your recent interview with David Tuller, you said about the dysregulation of the autonomic nervous system: "It is all a bit doubtful."

If I may ask, how would you explain this clinical entity when during a mild infection a healthy person develops an excessive orthostatic rise in heart rate — say, 70 bpm before infection and 130 bpm after — and this becomes chronic? How would you explain this, given that mechanical factors, "small heart," and deconditioning are clearly not the case, and as you mentioned in the interview, the HPA axis seems to be intact among patients?
 
That's what I see in a popular textbook of rheumatology FIRESTEIN & KELLEY’S TEXTBOOK OF RHEUMATOLOGY,
TWELFTH EDITION, Chapter 74 "Sjogren's syndrome" by E. WILLIAM ST. CLAIR AND DAVID L. LEVERENZ, page 1287:

That section is typically wooly and without objective figures. Unfortunately, we live in an age in which building clinical and research empires on this sort of waffle takes precedence over any hard data. I was recently talking to an expert on peripheral neuropathy who confirmed that tests for small fibre neuropathy are still largely meaningless. And 'may be associated with autonomic dysfunction' is about as vague as you can get. Special Sjogren's clinics are totally unrepresentative of the Sjogren's population as a whole.

Bascially it provides no factual evidence of a link and these days physicians will tend to suggest any link that fits with current fashion.
 
If I may ask, how would you explain this clinical entity when during a mild infection a healthy person develops an excessive orthostatic rise in heart rate — say, 70 bpm before infection and 130 bpm after — and this becomes chronic? How would you explain this, given that mechanical factors, "small heart," and deconditioning are clearly not the case, and as you mentioned in the interview, the HPA axis seems to be intact among patients?

There must be a mechanism involving adrenergic nerves to the heart but calling this 'dysautonomia' doesn't help anybody in my view. Dysautonomia ought to mean some failure of the autonomic system itself. I think it much more likely that after an infection the autonomic nervous system responds to abnormal signals that arise outside it. If the problem is in a hypothalamic origin of the sympathetic drive that is one thing. If it is irritability of pacemaker cells in the heart it is another. It doesn't help to bundle them together.

For a period of about five years I used to wake up most mornings with a pulse rate of 150. It sometimes occurred in the middle of the night. It would last about five minutes. I consulted a cardiologist who thought I was 'functional'. I tried a beta blocker but that was horrible. After five years it went away completely. The cardiologist was not in the slightest bothered that he could not explain it. I think there are a lot of things like this we do not understand. I think they are better described in their own right rather than using these vague terms like dysautonomia which nobody actually knows the meaning of.
 
There must be a mechanism involving adrenergic nerves to the heart but calling this 'dysautonomia' doesn't help anybody in my view. Dysautonomia ought to mean some failure of the autonomic system itself. I think it much more likely that after an infection the autonomic nervous system responds to abnormal signals that arise outside it. If the problem is in a hypothalamic origin of the sympathetic drive that is one thing. If it is irritability of pacemaker cells in the heart it is another. It doesn't help to bundle them together.
I think the example of pacemaker cell irritability has no connection with reality. I am not aware of any clinical examples of pathological pacemaker cell irritability causing orthostatic tachycardia. Most clinical examples of OI are seen in neuroimmune or neurodegenerative disorders such as LEMS, MSA, Sjögren's, diabetes, and Parkinson's disease. My view is that blood pressure and heart rate are mainly orchestrated by the autonomic nervous system and the endocrine system. And given the absence of clear HPA pathology, I would argue that dysregulation of the autonomic nervous system is far from doubtful.
 
But that does not mean that all are. People with ME/CFS do not have generalised features of autonomic failure as seen in these other conditions. So it is better not to lump them all together.
I believe involvement of organs and severity is different among such diseases. For example, aging-related orthostatic hypotension or autonomic disturbances of diabetes compared to aggressive MSA or AAG.

You say that people with ME/CFS do not have generalised features of autonomic failure. Photophobia, frequent urination, dry mouth, dry eyes, constipation or diarrhea, hypotension, orthostatic hypotension, orthostatic tachycardia, erectile dysfunction, gastric dysmotility, sweating issues, heat intolerance are reported symptoms, though their mechanisms remain unclear. Of course, not all patients experience them and someone has none.

1) What sources of information do you use when you say that people with ME/CFS don't have smth? My question is primarily about severe patients. I saw in another thread you mentioned Dr. Michael Zandi. Maybe Mr. Zandi visited very severe patients and assessed autonomic function?

2) Why do you think that nutritional failure is not caused by gastroparesis? I'm asking in the context of this discussion about autonomic dysfunction because one of the most common reasons of gastroparesis is diabetic autonomic neuropathy.
 
The answer to all these questions is that despite decades of investigation nothing concrete in the way of pathology has been documented. It may be there is some cases but we need facts rather than vague analogies.
From decades of investigation I am aware of the only one study of solid food gastric emptying but I am not sure it is relevant due to Fukuda criteria (doi:10.1186/1471-230X-4-32).

Despite some issues with standardisation, reproducibility and overlap with functional dyspepsia, gastric scintigraphy with solid meal is an established option to test motility. Another one is breath test.

As I mentioned above I believe that in the case of features of autonomic dysfunction accompanied by chronic nausea, vomiting, weight loss, bloating and early satiety, gastric emptying test after ruling out mechanical obstruction can be considered and discussed with a patient.

I agree that we need facts. I do not think that "SFN is not relevant" is a fact. I do not think that "the autonomic nervous system is intact" is a fact.
 
There remains that question of how to conduct medical care. Given the ongoing confusion of theory with fact, it is not necessarily a question that advocacy can resolve. But advocacy could confine itself to deterring irregular procedures. There is a question of irregular "diagnoses", as more and more proponents of the Functional Neurological Disorder theory are claiming that ME/CFS is not ME/CFS it is FND. When this fails, the claim is muted, toned down into a claim that FND is at least co-morbid.

And yet implausible FND proponents cannot conduct and will not allow a standard ME/CFS assessment. Once an FND ticket is placed on a medical file, it seems to confirm the long history of NHS speculation that mental illness causes physical problems. FND proponents do not object to any of that speculation. But none of all that "diagnostic procedure" neccessarily withstands scrutiny. Since NICE scrutinised evidence to radically revise its guideline, the NHS now accepts that an ME/CFS diagnosis is genuine, not a mental illness, not FND, and must not be dangerously confused with harmful mental illness.

And yet the signs of FND can still be dangerously confused with the symptoms of ME/CFS, exactly as defined in the guideline: endangering the "safeguarded" targets. In such case, the medical care and personal care (nursing) of ME/CFS is re-defined as medical abuse and terminated by blind dogma, with no ME/CFS assessment in sight. Another advocacable matter. Once FND is on the file, it is held to be co-morbid, even if one is dying with the spongiform brain disease. FND diagnosticians need to admit making mistakes.

This is now a large question of irregular FND and FII "diagnosis" perpetuated to terminate the previously established medical care of patients with ME/CFS. Medico-legal advocacy might help with that, as families across Europe report being terrorised. Terrorised over tube-feeds too. With a black mark on one's record once in the early stages of any intestinal reactivity restricting diet. This type of artificial controversialisation stops the NHS discussing the reactivity.

In Britain, this welfare state problem with the more extreme cases could have a lot to do with the general lack of long-term inpatient provision since selling off that part of the NHS estate, then siphoning off the funds for long-term outpatient provision too. But no long term prognosis can be determined while repeatedly disrupting the established nursing and medical care. The ME/CFS cases are challenged and any consensus on effective medical care is challenged. The stark difference in clinical attitudes within the NHS indicates an ongoing internal schism, powerful but still obscured, potentially lethal and impacting cases past, present and future.

However indeterminate the reactive innards, it is a problem broadly covered by the ME/CFS guideline as determined by NICE, hence this recently published medico-legal precedent The Local Authority v D & Anor. The precedent might apply, now that it is set by this anonymised judgement. Forward ME took it up, warning: "this statement contains material that some readers may find upsetting, including references to severe illness, safeguarding concerns, child protection proceedings, children and young people with very severe Myalgic Encephalomyelitis (ME/CFS) and family distress.".

Maybe it is time for NICE to explain how come it was persuaded to withdraw nutritional supplements for the unspecified medical conditions, the non-disease specific supplements which were there in December 2024 and then not there any more. This stopped NHS dietitians advising such prescriptions, around the same time NICE was asked to re-consider the matter in case of ME/CFS (and outsource its ME/CFS clinical knowledge).

Nutritional supplements (non-disease specific) | Borderline substances | BNF | NICE (as was)
https://bnf.nice.org.uk/borderline-substances/nutritional-supplements-non-disease-specific/
 
Last edited:
Back
Top Bottom